Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. The company is headquartered in Paris, Ile-De-France and currently employs 68 full-time employees. The company went IPO on 2015-06-26. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The firm's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.
최신 재무제표(Form-10K)에 따르면, ABIVAX Société Anonyme의 총 자산은 $0이며, 순損失입니다.
ABVX의 주요 재무 비율은 무엇인가요?
ABIVAX Société Anonyme의 유동비율은 0이고, 순이익률은 0, 주당 매출은 $0입니다.
ABIVAX Société Anonyme의 매출은 부문 또는 지역별로 어떻게 나뉘나요?
ABIVAX Société Anonyme 最大收入來源為 Concentrate Operations,在最近的收益報告中收入為 28,462,000,000。就地區而言,United States 是 ABIVAX Société Anonyme 的主要市場,收入為 19,127,000,000。
ABIVAX Société Anonyme은 수익성이 있나요?
無, 최신 재무제표에 따르면 ABIVAX Société Anonyme의 순損失은 $0입니다.